Accessibility Menu
Arrow-Thin-Down
S&P 500
6,728.80
+0.1%
+8.48
Arrow-Thin-Down
DJI
46,987.10
+0.2%
+74.80
Arrow-Thin-Down
NASDAQ
23,004.54
-0.2%
-49.46
Arrow-Thin-Down
Bitcoin
$102,129.00
+0.1%
+$139.01
Arrow-Thin-Down
AAPL
$268.57
-0.4%
-$1.20
Arrow-Thin-Down
AMZN
$244.60
+0.6%
+$1.56
Arrow-Thin-Down
GOOG
$279.81
-1.9%
-$5.53
Arrow-Thin-Down
META
$622.06
+0.5%
+$3.12
Arrow-Thin-Down
MSFT
$496.91
-0.0%
-$0.19
Arrow-Thin-Down
NVDA
$188.13
+0.0%
+$0.05
Arrow-Thin-Down
TSLA
$429.52
-3.7%
-$16.39
Daily Stock GainersDaily Stock LosersMost Active Stocks

Should You Buy Novo Nordisk After the Huge Investor Update?

By Parkev Tatevosian, CFA – Nov 9, 2025 at 5:02AM

Pharma companies are under pressure to lower prices in the U.S.

Novo Nordisk (NVO 1.89%) is struggling with competition in its weight loss treatment business and is looking to make an acquisition to bolster its pipeline of drugs.

*Stock prices used were the afternoon prices of Nov. 5, 2025. The video was published on Nov. 7, 2025.

About the Author

Parkev Tatevosian, CFA
A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.
TMFParkev
X@TMFParkev

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services